Zydus Cadila Joins IO Therapy League With XOMA Tie-up
IL-2 Therapy Use So Far Limited By Toxicities
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
